Matinas Biopharma (NYSEAMERICAN:MTNB) Releases Quarterly Earnings Results

Matinas Biopharma (NYSEAMERICAN:MTNB) announced its quarterly earnings data on Tuesday. The company reported ($0.26) earnings per share for the quarter, FiscalAI reports.

Matinas Biopharma Trading Down 11.8%

Shares of MTNB traded down $0.07 during mid-day trading on Tuesday, reaching $0.50. The company’s stock had a trading volume of 55,095 shares, compared to its average volume of 20,017. The stock has a market cap of $3.21 million, a PE ratio of -0.15 and a beta of 1.32. Matinas Biopharma has a 52 week low of $0.47 and a 52 week high of $3.09. The company’s fifty day moving average price is $0.61 and its two-hundred day moving average price is $0.98.

Hedge Funds Weigh In On Matinas Biopharma

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC bought a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma at the end of the most recent quarter. 11.77% of the stock is owned by hedge funds and other institutional investors.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.